• We believe outstanding clinical care is directly linked to an active program of clinical research. Our physician-scientists take the questions that arise in their clinical practices, answer them through clinical trials, and take this new knowledge back to the clinic where it can immediately benefit patients.

    Breast cancer investigators are tackling cancer on multiple fronts, including triple-negative breast cancers, HER2-positive breast tumors that have become resistant to Herceptin, and targeted therapies for metastatic breast cancer.

    Dana-Farber/Brigham and Women's Cancer Center's Breast Oncology Program provides breast cancer patients access to more than 40 clinical trials at a time — many of which are changing the standard of care worldwide and are not available elsewhere. Our clinical trials focus on the types and phases of your disease so therapy can be targeted to your type of breast cancer.

    Search

    Clinical trials for early stage breast cancer 

    Clinical trials for metastatic breast cancer 

    Clinical trials for breast cancer prevention  

    Patient advocates review clinical and translational research

    At the Susan F. Smith Center for Women’s Cancers, breast cancer patients are not only the beneficiaries of research advances; in a patient-centered approach, they help guide the research itself. The Breast Cancer Advocacy Group (BCAG), composed chiefly of breast cancer patients and survivors, provide a patient perspective to the Center's clinical investigators. The group reviews concepts and protocols for clinical trials from a patient’s perspective. For example, the advocates might recommend revisions to research questions so they more closely reflect the concerns of patients.

    The advocates are also members of project teams for the Breast SPORE (Specialized Program of Research Excellence) from the National Cancer Institute, reviewing applications for institutional and SPORE-funded Career Development Awards, and working hand-in-hand with investigators to design research studies.

    Learn more about breast cancer patient advocates, including how to become one.

    What distinguishes Dana-Farber research

    Dana-Farber remains true to Dr. Sidney Farber's vision of a cancer center as dedicated to discoveries in cancer research as it is to delivering compassionate, patient-centered care. Through strategic investment in research, we support scientific leaders and young investigators, acquire technology at the leading edge of cancer research, and ensure a spirit of collaboration and innovation.

    • Dana-Farber scientists are among the leading recipients of National Cancer Institute research grants, on a per-faculty-member basis, in the United States.
    • The pioneering efforts of our scientists are supported by more than $15 million in funds each year.
    • Our investigators lead close to 700 trials of potential therapies – studies that involve approximately 4,000 patients.
    • As one of the largest consortiums of cancer clinical research in the United States, Dana-Farber and its partners - collectively known as the Dana-Farber/Harvard - are able to offer an exceptional range of trials covering all major forms of cancer and a wide array of rarer forms.

    Read about our recent breast cancer research advances.